Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2024-08-12 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
关于三价HPV疫苗Ⅲ期临床试验揭盲结果的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the unblinding results of the Phase III clinical trial of their trivalent HPV vaccine. It details the clinical trial progress, interim analysis results, and subsequent steps including regulatory submission plans. The document is an announcement of clinical trial results and future regulatory plans, not a full financial report or detailed management discussion. It does not contain financial statements or detailed financial analysis. The document length is 1687 characters, which is relatively short and consistent with an announcement rather than a full report. There is no indication that this is an Annual Report, Interim Report, Earnings Release, or any other financial filing. It is also not a regulatory filing in the sense of compliance or officer certification. The content is primarily about clinical trial progress and regulatory submission plans, which fits best under Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-08-12 Chinese
关于全资子公司取得药品生产许可证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Kangle Weishi Biotechnology Co., Ltd. regarding its wholly-owned subsidiary obtaining a pharmaceutical production license. It includes details about the license, the issuing authority, and the impact on the company. The document is short (1043 characters) and serves as an official announcement of a regulatory approval rather than a financial report or detailed operational report. There is no financial data, no discussion of financial results, no management discussion, no voting results, or other report types. It is a regulatory announcement about a license acquisition, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-08-04 Chinese
关于注销部分募集资金专项账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation (注销) of certain special accounts for raised funds (募集资金专项账户) by Beijing 康乐卫士生物技术股份有限公司. It details the background of the fundraising, the management and use of the funds, and the specific accounts being closed after the funds have been fully used. The document includes references to regulatory approvals and agreements with banks and sponsors but does not contain financial statements or detailed financial performance data. The length is about 2043 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on capital management and account closure related to fundraising activities, which fits the category of Capital/Financing Update (CAP). It is not a full annual or interim report, audit report, or earnings release. Therefore, the best classification is Capital/Financing Update (CAP).
2024-07-29 Chinese
关于注销部分募集资金专项账户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation (注销) of certain special accounts for raised funds (募集资金专项账户) by Beijing Kangle Weishi Biotechnology Co., Ltd. It details the background of the fundraising activities, the management and use of the raised funds, and the specific bank accounts being closed. The document includes meeting dates, approvals, and agreements related to the fundraising and account management. It does not contain financial statements, audit opinions, or detailed financial results. The document is relatively short (4637 characters) and serves as a formal announcement about the status and cancellation of fundraising accounts rather than a full financial report or audit. Therefore, it fits best into the category of Capital/Financing Update (CAP), as it updates on the company's fundraising activities and capital management, specifically the cancellation of fundraising accounts.
2024-07-22 Chinese
关于发行境外上市外资股（H股）获中国证监会备案的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing 康乐卫士生物技术股份有限公司 regarding the filing and approval of its overseas listing of foreign shares (H shares) with the China Securities Regulatory Commission (CSRC). It details the number of shares to be issued, regulatory compliance requirements, and the need for further approvals from Hong Kong regulatory bodies. The document is short (917 characters) and serves as a formal notification of a capital market event related to the company's financing and listing activities. It is not a full financial report, earnings release, or management discussion, but rather an update on the company's capital raising and listing process. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2024-07-09 Chinese
北京观韬中茂律师事务所关于北京康乐卫士生物技术股份有限公司2024年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and procedural compliance of the company's 2024 second extraordinary general meeting (EGM). It details the convening, attendance, voting procedures, and results of the shareholders' meeting. The document does not contain financial statements or performance data but focuses on the legal validation of the meeting process and resolutions. It is not an announcement of voting results per se, but a legal opinion on the meeting's legality. Given the nature of the document as a legal opinion on a shareholders' meeting, it best fits the category of Regulatory Filings (RNS), which covers miscellaneous regulatory and compliance documents that do not fit other categories. The document length is under 5,000 characters and is not a report publication announcement. Therefore, the classification is RNS with high confidence.
2024-07-02 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.